The first patient in a Phase 1 study of Cellectis’ UCART123 has been administered with the gene-edited chimeric antigen receptor (CAR T) cells (UCART) at the MD Anderson Cancer Center in Texas. The treatment is aimed at a rare and aggressive form of acute myeloid leukemia (AML), Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
UCART123 is an allogeneic product which employs TALEN® gene edited CAR T cells derived from donors. The engineered cells target CD123, an antigen expressed at the surface of leukemic cells. The Phase 1 trial being led by professors at the MD Anderson Cancer Center will evaluate the safety and efficacy of UCART123. There are currently no treatments for the cancer, which has been compounded by its recent classification as a distinct clinicopathological entity.
Chief Medical Officer of Cellectis, Loan Hoang-Sayag, commented ‘We are eager to progress through clinical trials with UCART123, Cellectis’ wholly controlled gene-edited product candidate, next with the treatment of BPDCN, rare but aggressive entity. With this innovative treatment, the hope is that our “off-the-shelf” approach will transform the way we think about cancer care and serve as the next step in curing this disease through the power of gene editing.’
Source: Cellectis’ UCART123 Administered to First Patient with BPDCN in Phase I Clinical Trial at MD Anderson Cancer Center Press Release